Patent ID: 6133271
Filing Date: 2000-10-17
Classification: A61K

Abstract:
A method of treating a mammal having precancerous lesions sensitive to treatment with a compound of Formula I comprising administering a pharmacologically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof: ##STR6## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, hydroxy, A, OA, alkenyl, alkynyl, --NO.sub.2, --CF.sub.3 or halogen, with the proviso that one of R.sub.1 or R.sub.2 is not hydrogen;R.sub.3 and R.sub.4 are independently selected from the group consisting of hydrogen, A, --OA, halogen, --NO.sub.2, --NH.sub.2, --NHA or --NAA', or R.sub.3 and R.sub.4 are together form a moiety selected from the group consisting of --O--CH.sub.2 --CH.sub.2 --, --O--CH.sub.2 --O-- or --O--CH.sub.2 --CH.sub.2 --O,X is selected from the group consisting of an unsubstituted or a substituted 5-7 membered saturated or unsaturated ring, wherein the ring is selected from the group consisting of phenyl, cyclopentyl, cyclohexyl, cycloheptyl, furyl, dioxolanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridyl, piperidinyl, morpholinyl, pyranyl, dioxanyl, pyridazinyl, pyrimidinyl, piperazinyl, quinolyl, and isoquinolyl and wherein the substitutents on the ""X"" ring are one or two selected from the group consisting of -lower alkyl, COOH, --COOA, --CONH.sub.2, --CONAA', --CONHA, --CN, --CH.sub.2 COOH or --CH.sub.2 CH.sub.2 COOH;A and A' are independently selected from the group consisting of C.sub.1-6 alkyl; andn is 0, 1, 2 or 3; andphysiologically acceptable salts thereof.